DANCANN PHARMA DK-0375
DanCann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. It sources, develops, and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. The company's development pipeline includes EXT02 CannGros, EXT03 CannGros, EXT04 Cann… Read more
DANCANN PHARMA DK-0375 (DAN) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, DANCANN PHARMA DK-0375 (DAN) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
DANCANN PHARMA DK-0375 - Net Assets Trend (None–None)
This chart illustrates how DANCANN PHARMA DK-0375's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for DANCANN PHARMA DK-0375 (None–None)
The table below shows the annual net assets of DANCANN PHARMA DK-0375 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to DANCANN PHARMA DK-0375's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
DANCANN PHARMA DK-0375 Competitors by Market Cap
The table below lists competitors of DANCANN PHARMA DK-0375 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NAHL Group PLC
LSE:NAH
|
$2.46K |
|
Generation Alpha Inc
OTCQB:GNAL
|
$2.46K |
|
OROSUR MNG
BE:UR2
|
$2.46K |
|
FlexShopper Inc
NASDAQ:FPAY
|
$2.46K |
|
Frieslandcampina
KAR:FCEPL
|
$2.46K |
|
PowerHouse Energy Group Plc
LSE:PHE
|
$2.45K |
|
Aquila European Renewables Income PLC
LSE:AERI
|
$2.45K |
|
SFS REAL ESTATE INVESTMENT TRUST
XNSA:SFSREIT
|
$2.45K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DANCANN PHARMA DK-0375's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares DANCANN PHARMA DK-0375's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently DANCANN PHARMA DK-0375 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares DANCANN PHARMA DK-0375's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DANCANN PHARMA DK-0375 (DAN) | €- | N/A | N/A | $2.46K |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |